Kusum Healthcare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Kusum Healthcare Private Limited Pharmaceutical Export Portfolio Dataset — 13 Products, $21.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Kusum Healthcare Private Limited — Pharmaceutical Exporter Profile (2026) | 13 Products, $21.0M Trade | TransData Nexus

Kusum Healthcare Private Limited

Indian Pharmaceutical Exporter · Antifungals Specialist · $21.0M Total Trade · DGFT Verified

Kusum Healthcare Private Limited is an Indian pharmaceutical exporter with a total trade value of $21.0M across 13 products in 7 therapeutic categories. Based on 1,205 verified export shipments from Indian Customs (DGFT) records, Kusum Healthcare Private Limited is the #1 Indian exporter in 3 products including Ketoconazole, Biotin, Pyrantel. Top exports include Ketoconazole ($6.8M), Levofloxacin ($2.7M), Fluconazole ($2.2M).

Kusum Healthcare Private Limited — Export Portfolio & Destination Treemap

Kusum Healthcare Private Limited pharmaceutical export portfolio — 13 products across 7 therapeutic categories. Source: Indian Customs (DGFT).

Who is Kusum Healthcare Private Limited? — Company Overview & Market Position

Kusum Healthcare Private Limited, established on March 12, 1997, is a privately held pharmaceutical company headquartered in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U65929DL1997PTC085780. As of March 31, 2024, Kusum Healthcare reported an authorized capital of ₹10.00 crore and a paid-up capital of ₹7.99 crore. The company employs approximately 726 professionals, reflecting its significant presence in the pharmaceutical sector. Kusum Healthcare specializes in the formulation and development of finished pharmaceutical products, including tablets, capsules, syrups, and injections, across various therapeutic categories. The company's official website is www.kusumhealthcare.com.

What Does Kusum Healthcare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ketoconazole$6.8M 2Levofloxacin$2.7M

Product Portfolio — Top 13 by Export Value

Kusum Healthcare Private Limited exports 13 pharmaceutical products across 7 therapeutic categories. Market leader (#1 exporter) in 3 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ketoconazole	Antifungals	$6.8M	391	17.1%	1
2	Levofloxacin	Antibiotics	$2.7M	74	3.7%	6
3	Fluconazole	Antifungals	$2.2M	182	2.4%	9
4	Clotrimazole	Antifungals	$2.0M	142	2.1%	9
5	Leflunomide	Immunosuppressants	$1.3M	56	9.0%	3
6	Biotin	Vitamins & Supplements	$1.2M	63	76.4%	1
7	Zinc	Vitamins & Supplements	$1.1M	65	1.4%	14
8	Miconazole	Antifungals	$936.1K	47	4.7%	4
9	Pyrantel	Antimalarial & Antiparasitic	$736.8K	27	22.5%	1
10	Itraconazole	Antifungals	$701.4K	35	2.6%	11
11	Chlorpheniramine	Antihistamines & Allergy	$617.8K	30	1.3%	9
12	Ornidazole	Advanced Antibiotics	$504.7K	49	2.9%	4
13	Secnidazole	Advanced Antibiotics	$295.3K	44	1.0%	10

Kusum Healthcare Private Limited exports 13 pharmaceutical products across 7 therapeutic categories with a total export value of $21.0M. The company is the #1 Indian exporter in 3 products: Ketoconazole, Biotin, Pyrantel. The top category is Antifungals (59.8% of portfolio), followed by Antibiotics (12.8%), indicating a concentrated portfolio with the top 5 products accounting for 71.2% of total export value.

Kusum Healthcare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Kusum Healthcare operates manufacturing facilities in India, strategically located to serve both domestic and international markets. While specific details regarding plant locations and capacities are not publicly disclosed, the company's substantial export volume indicates robust manufacturing capabilities. The facilities are equipped to produce a diverse range of finished pharmaceutical formulations, adhering to international quality standards.

3Key Leadership

The leadership team at Kusum Healthcare comprises experienced professionals dedicated to steering the company's growth and operational excellence. Key executives include:

Sanjeev Gupta: Director
Badri Prasad Gupta: Director
Deepak Mangal: Director
Anil Tyagi: Director

These leaders bring a wealth of experience in the pharmaceutical industry, contributing to the company's strategic direction and success.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Kusum Healthcare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Kusum Healthcare has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has successfully navigated the regulatory landscapes of these regions, obtaining necessary approvals for its pharmaceutical products. This achievement underscores Kusum Healthcare's commitment to maintaining high-quality standards and compliance with international regulations. The company's ability to secure market access in these regions reflects its robust manufacturing processes and adherence to global pharmaceutical standards.

2Emerging Markets

Kusum Healthcare has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products have been prequalified by the World Health Organization (WHO), facilitating access to these regions. This prequalification enables Kusum Healthcare to supply essential medicines to countries with critical healthcare needs, enhancing its global reach and impact. The company's focus on emerging markets aligns with its mission to provide quality healthcare solutions worldwide.

3Geographic Strategy

Kusum Healthcare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Kusum Healthcare has achieved significant milestones in the United States market. The company has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with stringent regulatory standards. Additionally, Kusum Healthcare has received approval for Abbreviated New Drug Applications (ANDAs), allowing it to market generic pharmaceutical products in the U.S. The company has also filed Drug Master Files (DMFs) with the FDA, providing detailed information about its manufacturing processes and quality control measures. These accomplishments reflect Kusum Healthcare's commitment to maintaining high-quality standards and regulatory compliance in the U.S. market.

2WHO & EU GMP

Kusum Healthcare has obtained prequalification from the World Health Organization (WHO), affirming the quality, safety, and efficacy of its pharmaceutical products. This prequalification facilitates the company's entry into international markets, particularly those with stringent regulatory requirements. The company has also secured Good Manufacturing Practice (GMP) certifications from the European Union (EU), demonstrating adherence to international manufacturing standards. These certifications underscore Kusum Healthcare's dedication to producing high-quality pharmaceutical products for global markets.

Kusum Healthcare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Kusum Healthcare operates in a competitive pharmaceutical market, facing competition from both domestic and international companies. While specific market share data is not publicly disclosed, the company's substantial export value of $21.0 million USD and its presence in multiple therapeutic categories indicate a significant market position. The company's focus on high-demand segments such as Antifungals, Antibiotics, and Vitamins & Supplements positions it favorably against competitors in these areas. Kusum Healthcare's ability to secure regulatory approvals in diverse markets further enhances its competitive standing.

2Key Differentiators

Kusum Healthcare's key differentiators include its comprehensive product portfolio, encompassing 13 products across 7 therapeutic categories, with a concentration in high-demand segments. The company's leadership in markets for Ketoconazole, Biotin, and Pyrantel underscores its expertise in these areas. Additionally, Kusum Healthcare's commitment to quality is evidenced by its WHO prequalification and EU GMP certifications, ensuring adherence to international manufacturing standards. The company's strategic geographic diversification and focus on emerging markets further distinguish it in the global pharmaceutical landscape.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Kusum Healthcare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Kusum Healthcare demonstrates a strong track record as a pharmaceutical exporter, with a total export value of $21.0 million USD and 1,205 shipments across 13 products in 7 therapeutic categories. The company's portfolio concentration, with the top 5 products accounting for 71.2% of exports, indicates a focused approach to high-demand segments. The absence of publicly available records indicating regulatory non-compliance further underscores the company's reliability as a supplier. Kusum Healthcare's adherence to international quality standards, as evidenced by its WHO prequalification and EU GMP certifications, enhances its reputation for consistency and quality.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Facility Registration: Confirm the registration status of Kusum Healthcare's manufacturing facilities with the U.S. Food and Drug Administration (FDA).

WHO Prequalification: Verify the World Health Organization's prequalification status of Kusum Healthcare's products.

Frequently Asked Questions — Kusum Healthcare Private Limited

How many pharmaceutical products does Kusum Healthcare Private Limited export from India?

Kusum Healthcare Private Limited exports 13 pharmaceutical products across 7 therapeutic categories. The top exports are Ketoconazole ($6.8M), Levofloxacin ($2.7M), Fluconazole ($2.2M), Clotrimazole ($2.0M), Leflunomide ($1.3M). Total export value is $21.0M.

What is Kusum Healthcare Private Limited's total pharmaceutical export value?

Kusum Healthcare Private Limited's total pharmaceutical export value is $21.0M, based on 1,205 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Kusum Healthcare Private Limited the #1 Indian exporter?

Kusum Healthcare Private Limited is the #1 Indian exporter in 3 products: Ketoconazole (17.1% market share), Biotin (76.4% market share), Pyrantel (22.5% market share).

What therapeutic categories does Kusum Healthcare Private Limited cover?

Kusum Healthcare Private Limited exports across 7 therapeutic categories. The largest are Antifungals (59.8%, 5 products), Antibiotics (12.8%, 1 products), Vitamins & Supplements (10.8%, 2 products).

Get Full Kusum Healthcare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.